Daclatasvir (BioDeep_00000715660)
代谢物信息卡片
Daclatasvir (BMS-790052)
化学式: C40H50N8O6 (738.3853)
中文名称: 达卡他伟双盐酸盐, 达卡他韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
InChI: InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AP - Antivirals for treatment of hcv infections
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C254 - Anti-Infective Agent > C281 - Antiviral Agent
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
3 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:82977
- KEGGdrug: D10065
- PubChem: 25154714
- DrugBank: DB09102
- ChEMBL: CHEMBL2023898
- CAS: 1214735-16-6
- CAS: 1009119-64-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Ahmad Fariz Malvi Zamzam Zein, Catur Setiya Sulistiyana, Wilson Matthew Raffaello, Arief Wibowo, Raymond Pranata. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment.
Postgraduate medical journal.
2022 Jul; 98(1161):509-514. doi:
10.1136/postgradmedj-2021-140287. [PMID: 34103373] - Sara Mobarak, Mehdi Salasi, Ahmad Hormati, Javad Khodadadi, Masood Ziaee, Farshid Abedi, Azadeh Ebrahimzadeh, Zohreh Azarkar, Fariborz Mansour-Ghanaei, Farahnaz Joukar, Sara Yeganeh, Tofigh Yaghubi Kalurazi, Mohammadreza Naghipour, Zeinab Mehrabi, Amir Reza Bahadori, Shoeleh Yaghoubi, Rohollah Moslemi, Hamideh Abbaspour Kasgari, Hafez Fakheri, Minoo Moghimi, Amir Mohammad Shabani, Zahra Nekoukar, Farhang Babamahmoodi, Ali Reza Davoudi Badabi, Lotfollah Davoodi, Mehdi Hassaniazad, Elham Barahimi, Abdolali Tousi, Anahita Sadeghi, Hadiseh Hosamirudsari, Ali Ali Asgari, Mohammad Abdollahi, Amir Anushiravani, Minoosh Shabani, Shervin Shokouhi, Nasim Khajavirad, Mohammadreza Salehi, Seyed Ali Dehghan Manshadi, Hashem Mousavi, Farnaz Zolfaghari, Elmira Azimi, Aida Zeinali, Elham Akbarpour, Dorsa Merat, Gholamali Eslami, Sajedeh Mousaviasl, Sara Sayar, Esmat Radmanesh, Mona Ebrahimzadeh, Zahra Arizavi, Saeed Jelvay, Shokrollah Salmanzadeh, Hani Esmaeilian, Morteza Mobarak, Jalal Karimi, Zahra Poormontaseri, Nasrollah Hasooni Bahrini, Atefeh Bonyadi, Fatemeh Dehghani, Hadi Mirzaei, Masoome Noori Jangi, Hossein Pourmasoomi, Lili Rezaie Keikhaie, Mahdi Afshari, Alireza Nateghi Baygi, Helia Nateghi Baygi, Jacob Levi, Kaitlyn McCann, Hannah Wentzel, Bryony Simmons, Andrew Hill, Shahin Merat. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER).
The Journal of antimicrobial chemotherapy.
2022 02; 77(3):758-766. doi:
10.1093/jac/dkab433. [PMID: 34849957] - Mahmoud El-Bendary, Sherief Abd-Elsalam, Tamer Elbaz, Wafaa El-Akel, Ahmed Cordie, Tamer Elhadidy, Hatem Elalfy, Khaled Farid, Mohamed Elegezy, Adel El-Badrawy, Mustafa Neamatallah, Mohamed Abd Elghafar, Marwa Salama, Mohamed AbdAllah, Mahmoud Essam, Mostafa El-Shazly, Gamal Esmat. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.
Expert review of anti-infective therapy.
2022 02; 20(2):291-295. doi:
10.1080/14787210.2021.1950532. [PMID: 34225541] - Ilaria Mastrorosa, Massimo Tempestilli, Stefania Notari, Patrizia Lorenzini, Gabriele Fabbri, Elisabetta Grilli, Rita Bellagamba, Alessandra Vergori, Stefania Cicalini, Adriana Ammassari, Chiara Agrati, Andrea Antinori. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
European journal of drug metabolism and pharmacokinetics.
2022 Jan; 47(1):135-142. doi:
10.1007/s13318-021-00725-w. [PMID: 34623616] - Mahmoud Abdo, Ahmed Rabiee, Zeinab Abdellatif, Shereen Abdel Alem, Ahmed Moustafa. Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
European journal of gastroenterology & hepatology.
2021 12; 33(12):1588-1594. doi:
10.1097/meg.0000000000001903. [PMID: 32804853] - Sherif Abbass, Ehab Kamal, Mohsen Salama, Tary Salman, Alyaa Sabry, Wael Abdel-Razek, Sherine Helmy, Ahmed Abdelgwad, Neamt Sakr, Mohamed Elgazzar, Mohamed Einar, Mahmoud Farouk, Mounir Saif, Ismail Shehab, Eman El-Hosieny, Mai Mansour, Doaa Mahdi, El-Sayed Tharwa, Mostafa Salah, Ola Elrouby, Imam Waked. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial.
Journal of medical virology.
2021 12; 93(12):6750-6759. doi:
10.1002/jmv.27264. [PMID: 34379337] - Abdullahi Tsanni. African scientists race to test COVID drugs - but face major hurdles.
Nature.
2021 11; 599(7883):25-27. doi:
10.1038/d41586-021-02995-5. [PMID: 34732862] - Sonia Younas, Hamid Mukhtar, Umar Farooq Gohar, Abdullah Alsrhani, Badr Alzahrani, Kashaf Junaid, Muhammad Usman Qamar, Hasan Ejaz. Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients.
Journal of infection in developing countries.
2021 10; 15(10):1489-1496. doi:
10.3855/jidc.12912. [PMID: 34780372] - Chih-Cheng Lai, Chien-Ming Chao, Po-Ren Hsueh. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
2021 Oct; 54(5):767-775. doi:
10.1016/j.jmii.2021.05.011. [PMID: 34253490] - Yun-Sook Lim, Lap P Nguyen, Gun-Hee Lee, Sung-Geun Lee, Kwang-Soo Lyoo, Bumseok Kim, Soon B Hwang. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Molecules and cells.
2021 Sep; 44(9):688-695. doi:
10.14348/molcells.2021.0076. [PMID: 34518443] - Amit Goel, Dharmendra S Bhadauria, Anupma Kaul, Abhai Verma, Prachi Tiwari, Sumit Rungta, Praveer Rai, Amit Gupta, Rakesh Aggarwal. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2021 09; 36(10):1867-1871. doi:
10.1093/ndt/gfaa187. [PMID: 33097949] - Abolghasem Jouyban, Mir Ali Farajzadeh, Fariba Khodadadeian, Maryam Khoubnasabjafari, Mohammad Reza Afshar Mogaddam. Development of a deep eutectic solvent-based ultrasound-assisted homogenous liquid-liquid microextraction method for simultaneous extraction of daclatasvir and sofosbuvir from urine samples.
Journal of pharmaceutical and biomedical analysis.
2021 Sep; 204(?):114254. doi:
10.1016/j.jpba.2021.114254. [PMID: 34256327] - Li-Ping Shi, Xue Yang, Fang Liu, Jun-Gang Yin, Jing-Mei Yu, Jun Zhang, Hui Wang, Chong Zou, Meng Jiang. Bioequivalence of daclatasvir hydrochloride tablets in healthy Chinese subjects.
International journal of clinical pharmacology and therapeutics.
2021 Aug; 59(8):585-592. doi:
10.5414/cp203895. [PMID: 34032204] - Nazim Hussain, Nimrah Farooq, Muhammad Maqsood, Muhammad Shahid Riaz Rajoka, Muhammad Bilal. Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
Archives of microbiology.
2021 Jul; 203(5):2365-2371. doi:
10.1007/s00203-021-02233-6. [PMID: 33660021] - Kota Kurosaki, Yoshihiro Uesawa. Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions.
Biomolecules.
2021 06; 11(7):. doi:
10.3390/biom11070944. [PMID: 34202146] - Carolina Q Sacramento, Natalia Fintelman-Rodrigues, Jairo R Temerozo, Aline de Paula Dias Da Silva, Suelen da Silva Gomes Dias, Carine Dos Santos da Silva, André C Ferreira, Mayara Mattos, Camila R R Pão, Caroline S de Freitas, Vinicius Cardoso Soares, Lucas Villas Bôas Hoelz, Tácio Vinício Amorim Fernandes, Frederico Silva Castelo Branco, Mônica Macedo Bastos, Núbia Boechat, Felipe B Saraiva, Marcelo Alves Ferreira, Steffen Jockusch, Xuanting Wang, Chuanjuan Tao, Minchen Chien, Wei Xie, Dinshaw Patel, Aitor Garzia, Thomas Tuschl, James J Russo, Rajith K R Rajoli, Carolina S G Pedrosa, Gabriela Vitória, Letícia R Q Souza, Livia Goto-Silva, Marilia Zaluar Guimarães, Stevens K Rehen, Andrew Owen, Fernando A Bozza, Dumith Chequer Bou-Habib, Jingyue Ju, Patrícia T Bozza, Thiago Moreno L Souza. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
The Journal of antimicrobial chemotherapy.
2021 06; 76(7):1874-1885. doi:
10.1093/jac/dkab072. [PMID: 33880524] - Kiarash Keyvan, Mahmoud Reza Sohrabi, Fereshteh Motiee. Improved spectral resolution for the rapid simultaneous spectrophotometric determination of sofosbuvir and daclatasvir as anti hepatitis C virus drugs in pharmaceutical formulation and biological fluid using continuous wavelet and derivative transform.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2021 Apr; 251(?):119429. doi:
10.1016/j.saa.2021.119429. [PMID: 33477087] - Mohamed Darwish Ahmed Abd Alla, Reham M Dawood, Hassan Abd El-Hafeth Rashed, Galal Farrag, Islam Abdelmawla Emran Ammar, Mohamed Mahmoud Abdel-Halim Mahmoud, Ghada M Salum, Ahmed Mohamed Abdulhamid Altanbouly, Mai A El Meguid, Mostafa K El Awady. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
Archives of virology.
2021 Apr; 166(4):1071-1081. doi:
10.1007/s00705-021-04969-4. [PMID: 33533976] - Hirohito Yoneyama, Asahiro Morishita, Hisakazu Iwama, Koji Fujita, Takahiro Masaki, Joji Tani, Tomoko Tadokoro, Takako Nomura, Teppei Sakamoto, Kyoko Oura, Kei Takuma, Mai Nakahara, Shima Mimura, Akihiro Deguchi, Makoto Oryu, Kunihiko Tsutsui, Takashi Himoto, Kunitada Shimotohno, Takaji Wakita, Hideki Kobara, Tsutomu Masaki. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
Journal of gastroenterology and hepatology.
2021 Apr; 36(4):1126-1135. doi:
10.1111/jgh.15224. [PMID: 32839985] - Huan-Tee Chan, Chien-Ming Chao, Chih-Cheng Lai. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.
The Journal of infection.
2021 04; 82(4):e34-e35. doi:
10.1016/j.jinf.2020.12.021. [PMID: 33373651] - Tzu-Sheng Cheng, Po-Cheng Liang, Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Ping-Hsin Hsieh, Wan-Long Chuang, Ming-Lung Yu. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
The Kaohsiung journal of medical sciences.
2021 Apr; 37(4):334-345. doi:
10.1002/kjm2.12315. [PMID: 33151016] - Anthony A Stephenson, Sheng Cao, David J Taggart, Vinod P Vyavahare, Zucai Suo. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
European journal of medicinal chemistry.
2021 Mar; 213(?):113135. doi:
10.1016/j.ejmech.2020.113135. [PMID: 33454548] - Fatemeh Roozbeh, Majid Saeedi, Reza Alizadeh-Navaei, Akbar Hedayatizadeh-Omran, Shahin Merat, Hannah Wentzel, Jacob Levi, Andrew Hill, Amir Shamshirian. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
The Journal of antimicrobial chemotherapy.
2021 02; 76(3):753-757. doi:
10.1093/jac/dkaa501. [PMID: 33338232] - Bryony Simmons, Hannah Wentzel, Sara Mobarak, Gholamali Eslami, Anahita Sadeghi, Ali Ali Asgari, Hamideh Abbaspour Kasgari, Hafez Tirgar Fakheri, Shahin Merat, Andrew Hill. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
The Journal of antimicrobial chemotherapy.
2021 01; 76(2):286-291. doi:
10.1093/jac/dkaa418. [PMID: 33063117] - Young Joo Han, Keum Hwa Lee, Sojung Yoon, Seoung Wan Nam, Seohyun Ryu, Dawon Seong, Jae Seok Kim, Jun Young Lee, Jae Won Yang, Jinhee Lee, Ai Koyanagi, Sung Hwi Hong, Elena Dragioti, Joaquim Radua, Lee Smith, Hans Oh, Ramy Abou Ghayda, Andreas Kronbichler, Maria Effenberger, Daniela Kresse, Sara Denicolò, Woosun Kang, Louis Jacob, Hanwul Shin, Jae Il Shin. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
Theranostics.
2021; 11(3):1207-1231. doi:
10.7150/thno.48342. [PMID: 33391531] - Rasha Eletreby, Mahmoud Anees, Mariam Naguib, Abdelrahman Kobtan, Amal Helmy, Nahla Khalaf, Shimaa Mansour, Mohamed Hassany, Wafaa El Akel, Ahmed Hashem, Wahid Doss, Gamal Esmat. The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.
Expert review of gastroenterology & hepatology.
2021 Jan; 15(1):103-110. doi:
10.1080/17474124.2020.1823831. [PMID: 32933323] - Mohamed El-Nabarawi, Mohamed Nafady, Shahira Elmenshawe, Marwa Elkarmalawy, Mahmoud Teaima. Liver Targeting of Daclatasvir via Tailoring Sterically Stabilized Bilosomes: Fabrication, Comparative In Vitro/In Vivo Appraisal and Biodistribution Studies.
International journal of nanomedicine.
2021; 16(?):6413-6426. doi:
10.2147/ijn.s319255. [PMID: 34556987] - Eloi Chevallier, Matthias Büchler, Sophie Caillard, Nicolas Bouvier, Charlotte Colosio, Joseph Rivalan, Johnny Sayegh, Dominique Bertrand, Yannick Le Meur, Antoine Thierry, Cyril Garrouste, Jean-Philippe Rerolle, Lionel Rostaing, Philippe Gatault. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
Transplantation proceedings.
2020 Dec; 52(10):3179-3185. doi:
10.1016/j.transproceed.2020.06.005. [PMID: 32636068] - Christopher D Ma, Michio Imamura, Daniel C Talley, Adam Rolt, Xin Xu, Amy Q Wang, Derek Le, Takuro Uchida, Mitsutaka Osawa, Yuji Teraoka, Kelin Li, Xin Hu, Seung Bum Park, Nishanth Chalasani, Parker H Irvin, Andres E Dulcey, Noel Southall, Juan J Marugan, Zongyi Hu, Kazuaki Chayama, Kevin J Frankowski, Tsanyang Jake Liang. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.
Nature microbiology.
2020 12; 5(12):1532-1541. doi:
10.1038/s41564-020-0781-2. [PMID: 32868923] - Hamideh Abbaspour Kasgari, Siavash Moradi, Amir Mohammad Shabani, Farhang Babamahmoodi, Ali Reza Davoudi Badabi, Lotfollah Davoudi, Ahmad Alikhani, Akbar Hedayatizadeh Omran, Majid Saeedi, Shahin Merat, Hannah Wentzel, Anna Garratt, Jacob Levi, Bryony Simmons, Andrew Hill, Hafez Tirgar Fakheri. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
The Journal of antimicrobial chemotherapy.
2020 11; 75(11):3373-3378. doi:
10.1093/jac/dkaa332. [PMID: 32812025] - Anahita Sadeghi, Ali Ali Asgari, Alireza Norouzi, Zahedin Kheiri, Amir Anushirvani, Mahnaz Montazeri, Hadiseh Hosamirudsai, Shirin Afhami, Elham Akbarpour, Rasoul Aliannejad, Amir Reza Radmard, Amir H Davarpanah, Jacob Levi, Hannah Wentzel, Ambar Qavi, Anna Garratt, Bryony Simmons, Andrew Hill, Shahin Merat. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
The Journal of antimicrobial chemotherapy.
2020 11; 75(11):3379-3385. doi:
10.1093/jac/dkaa334. [PMID: 32812039] - Gholamali Eslami, Sajedeh Mousaviasl, Esmat Radmanesh, Saeed Jelvay, Saeid Bitaraf, Bryony Simmons, Hannah Wentzel, Andrew Hill, Anahita Sadeghi, James Freeman, Shokrollah Salmanzadeh, Hani Esmaeilian, Morteza Mobarak, Ramin Tabibi, Amir Hosein Jafari Kashi, Zahra Lotfi, Seyed Mehdi Talebzadeh, Aseni Wickramatillake, Mahboobeh Momtazan, Majid Hajizadeh Farsani, Sedigheh Marjani, Sara Mobarak. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
The Journal of antimicrobial chemotherapy.
2020 11; 75(11):3366-3372. doi:
10.1093/jac/dkaa331. [PMID: 32812051] - Chung-Feng Huang, Chia-Yen Dai, Ming-Lun Yeh, Ching-I Huang, Hsiang-Chun Lee, Wen-Ter Lai, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
The Kaohsiung journal of medical sciences.
2020 Nov; 36(11):920-928. doi:
10.1002/kjm2.12275. [PMID: 32643842] - Juan Li, Dong-Bo Wu, Wei Jiang, Xue-Bin Chen, Gui-Bao Xiao, Yong-Hong Wang, Meng-Lan Wang, Ya-Chao Tao, En-Qiang Chen. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Medicine.
2020 Oct; 99(43):e22726. doi:
10.1097/md.0000000000022726. [PMID: 33120769] - Hany M Elsadek, Elsayed S Abdelbaser, Mohamed H Emara, Hanan H Soliman, Alaa A Farag. Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
European journal of gastroenterology & hepatology.
2020 08; 32(8):1046-1053. doi:
10.1097/meg.0000000000001695. [PMID: 33216478] - Shereen A Saleh, Mohamed M Salama, Marwan M Alhusseini, Ghada A Mohamed. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
World journal of gastroenterology.
2020 Jun; 26(21):2864-2876. doi:
10.3748/wjg.v26.i21.2864. [PMID: 32550761] - Roberto Rossotti, Alessandro Tavelli, Stefano Bonora, Antonella Cingolani, Sergio Lo Caputo, Annalisa Saracino, Alessandro Soria, Letizia Marinaro, Caterina Uberti-Foppa, Cristina Mussini, Massimo Puoti, Antonella d'Arminio Monforte. Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2020 04; 52(4):447-451. doi:
10.1016/j.dld.2019.12.007. [PMID: 31959479] - Chung-Feng Huang, Ming-Lung Yu. Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection.
Kidney international.
2020 03; 97(3):615. doi:
10.1016/j.kint.2019.10.033. [PMID: 32087891] - Emanuela Zappulo, Riccardo Scotto, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Biagio Pinchera, Ivan Gentile. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Expert opinion on pharmacotherapy.
2020 Feb; 21(3):261-273. doi:
10.1080/14656566.2019.1697674. [PMID: 31914336] - Yuhei Saito, Michio Imamura, Takuro Uchida, Mitsutaka Osawa, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Masahiro Serikawa, Hiroshi Aikata, Hiromi Abe-Chayama, C Nelson Hayes, Kazuaki Chayama. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Journal of medical virology.
2020 02; 92(2):210-218. doi:
10.1002/jmv.25602. [PMID: 31584207] - K S Abdelkawy, S M El-Haggar, D H Ziada, N F Ebaid, M A El-Magd, F A Elbarbry. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2020 Jan; 121(?):109657. doi:
10.1016/j.biopha.2019.109657. [PMID: 31810127] - Ting Lin, Xipei Wang, Hongbo Gao, Zhonglin Feng, Lixia Xu, Jianchao Ma, Zhuo Li, Li Zhang, Renwei Huang, Xinling Liang, Shuangxin Liu. Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Blood purification.
2020; 49(6):692-699. doi:
10.1159/000499161. [PMID: 32289799] - Mogeb M Al-Nahari, Maggie M Abbassi, Fatma Se Ebeid, Mohamed Hassany, Manal H El-Sayed, Samar F Farid. Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.
Antiviral therapy.
2020; 25(2):101-110. doi:
10.3851/imp3357. [PMID: 32367815] - Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
Canadian journal of gastroenterology & hepatology.
2020; 2020(?):1632959. doi:
10.1155/2020/1632959. [PMID: 32083035] - Hany Aly Hussein, Ahmed Samir Allam, Ahmed Samir Abdel Moaty. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Current diabetes reviews.
2020; 16(2):165-170. doi:
10.2174/1573399815666190531091128. [PMID: 31146663] - Fernanda Bellini Lunardi Michels, Ana Cristina de Castro Amaral, Roberto José de Carvalho-Filho, Gustavo de Almeida Vieira, Ana Lucia da Silva Souza, Maria Lucia Gomes Ferraz. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.
Arquivos de gastroenterologia.
2020 Jan; 57(1):45-49. doi:
10.1590/s0004-2803.202000000-09. [PMID: 32294735] - Sherin Zakaria, Alaa E El-Sisi. Daclatasvir and Sofosbuvir Mitigate Hepatic Fibrosis Through Downregulation of TNF-α / NF-κB Signaling Pathway.
Current molecular pharmacology.
2020; 13(4):318-327. doi:
10.2174/1874467213666200116114919. [PMID: 31951178] - Giovana Rossato, Cristiane Valle Tovo, Paulo Roberto Lerias de Almeida. Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
2020 Jan; 24(1):25-29. doi:
10.1016/j.bjid.2019.10.011. [PMID: 31760038] - Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Nefrologia.
2020 Jan; 40(1):46-52. doi:
10.1016/j.nefro.2019.03.013. [PMID: 31229261] - Prasanta Debnath, Sanjay Chandnani, Pravin Rathi, Sujit Nair, Vinay Pawar, Qais Contractor. COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS.
Arquivos de gastroenterologia.
2020 Jan; 57(1):39-44. doi:
10.1590/s0004-2803.202000000-08. [PMID: 32294734] - Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Kuan-Yu Chen, Yu-Min Ko, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir.
Journal of gastroenterology and hepatology.
2020 Jan; 35(1):151-156. doi:
10.1111/jgh.14815. [PMID: 31373037] - Amany A Ghazy, Eman M Osman, Eman A Rashwan, Ahmed H Gaballah, Hanan Mostafa, Salwa Tawfik. Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients.
Journal of medical virology.
2019 12; 91(12):2166-2173. doi:
10.1002/jmv.25559. [PMID: 31368531] - Shafiq Ur Rehman Cheema, Muhammad Salman Rehman, Ghulam Hussain, Sidra Shafiq Cheema, Nooman Gilani. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial.
BMC nephrology.
2019 11; 20(1):438. doi:
10.1186/s12882-019-1631-4. [PMID: 31779583] - Johannes Wiegand, Peter Buggisch, Stefan Mauss, Klaus H W Boeker, Hartwig Klinker, Tobias Müller, Rainer Günther, Yvonne Serfert, Michael P Manns, Stefan Zeuzem, Thomas Berg, Holger Hinrichsen, German Hepatitis C-Registry. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
European journal of gastroenterology & hepatology.
2019 Nov; 31(11):1424-1431. doi:
10.1097/meg.0000000000001426. [PMID: 31589184] - Aya A Youssef, N Magdy, Lobna A Hussein, A M El-Kosasy. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Journal of chromatographic science.
2019 Aug; 57(7):636-643. doi:
10.1093/chromsci/bmz038. [PMID: 31063182] - Mohamed Oraby, Ahmed Khorshed, Eman Abdul-Rahman, Ramadan Ali, Mohamed M Elsutohy. A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine.
Journal of pharmaceutical and biomedical analysis.
2019 Jul; 171(?):104-110. doi:
10.1016/j.jpba.2019.03.065. [PMID: 30981192] - Huidong Gu, Yue Zhao, Marissa DeMichele, Naiyu Zheng, Yan J Zhang, Renuka Pillutla, Jianing Zeng. Eliminating Preparation of Multisample External Calibration Curves and Dilution of Study Samples Using the Multiple Isotopologue Reaction Monitoring (MIRM) Technique in Quantitative LC-MS/MS Bioanalysis.
Analytical chemistry.
2019 07; 91(13):8652-8659. doi:
10.1021/acs.analchem.9b02136. [PMID: 31180205] - Davide Ferrari, Sabrina Bagaglio, Michele Raso, Laura Galli, Simone Premaschi, Emanuela Messina, Giulia Morsica, Massimo Locatelli, Caterina Uberti-Foppa, Hamid Hasson. A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Jul; 1120(?):1-7. doi:
10.1016/j.jchromb.2019.04.048. [PMID: 31055190] - Hong Xiao, Jun Chen, Jiangrong Wang, Juhua Li, Feia Yang, Hongzhou Lu. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Medicine.
2019 Jul; 98(30):e16524. doi:
10.1097/md.0000000000016524. [PMID: 31348267] - Wei-Ping Lee, Keng-Li Lan, Shi-Xian Liao, Yi-Hsiang Huang, Ming-Chih Hou, Keng-Hsin Lan. Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus.
Journal of the Chinese Medical Association : JCMA.
2019 May; 82(5):368-374. doi:
10.1097/jcma.0000000000000095. [PMID: 30920421] - Pin-Nan Cheng, Yen-Cheng Chiu, Shih-Chieh Chien, Hung-Chih Chiu. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Journal of the Formosan Medical Association = Taiwan yi zhi.
2019 May; 118(5):907-913. doi:
10.1016/j.jfma.2018.09.016. [PMID: 30316677] - Maha A Sultan, Maha M Abou El-Alamin, Alastair W Wark, Marwa M Azab. Stability-indicating micellar enhanced spectro-fluorometric determination of Daclatasvir in its tablet and spiked human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2019 Mar; 211(?):52-58. doi:
10.1016/j.saa.2018.11.023. [PMID: 30503988] - Amit Goel, Dharmendra S Bhadauria, Anupma Kaul, Prashant Verma, Mayank Mehrotra, Amit Gupta, Raj K Sharma, Praveer Rai, Rakesh Aggarwal. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Nephrology (Carlton, Vic.).
2019 Mar; 24(3):316-321. doi:
10.1111/nep.13222. [PMID: 29327401] - Michael Duerr, Eva V Schrezenmeier, Lukas J Lehner, Léon Bergfeld, Petra Glander, Stephan R Marticorena Garcia, Christian E Althoff, Ingolf Sack, Susanne Brakemeier, Kai-Uwe Eckardt, Klemens Budde, Fabian Halleck. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
BMC nephrology.
2019 02; 20(1):36. doi:
10.1186/s12882-019-1218-0. [PMID: 30717681] - Eva Schrezenmeier, Friederike Hoffmann, Carsten Jaeger, Jens Schrezenmeier, Jan Lisec, Petra Glander, Engi Algharably, Reinhold Kreutz, Klemens Budde, Michael Duerr, Fabian Halleck. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
Therapeutic drug monitoring.
2019 02; 41(1):53-58. doi:
10.1097/ftd.0000000000000567. [PMID: 30422962] - Hongfeng Huang, Huanna Tang, Hao Deng, Jia Shen, Qin Zhou, Wenqing Xie, Jianyong Wu, Jianghua Chen. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
Transplant infectious disease : an official journal of the Transplantation Society.
2019 Feb; 21(1):e13018. doi:
10.1111/tid.13018. [PMID: 30369001] - Ayush Jain, Bhupinder Singh Kalra, Siddharth Srivastava, Shalini Chawla. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.
2019 Feb; 38(1):39-43. doi:
10.1007/s12664-019-00935-w. [PMID: 30710219] - Mohamed A Abdel-Lateef, Mahmoud A Omar, Ramadan Ali, Sayed M Derayea. Micellar spectrofluorimetric protocol for the innovative determination of HCV antiviral (daclatasvir) with enhanced sensitivity: Application to human plasma and stability study.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2019 Jan; 206(?):57-64. doi:
10.1016/j.saa.2018.07.101. [PMID: 30081268] - Keizo Kato, Noritomo Shimada, Masanori Atsukawa, Hiroshi Abe, Norio Itokawa, Yoshihiro Matsumoto, Rie Agata, Akihito Tsubota. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
PloS one.
2019; 14(7):e0219022. doi:
10.1371/journal.pone.0219022. [PMID: 31291311] - Vanessa D Costa, Carlos E Brandão-Mello, Estevão P Nunes, Pedro Guilherme Corôa Dos Santos Silva, Lia Laura Lewis Ximenez de Souza Rodrigues, Elisabeth Lampe, Francisco Campello do Amaral Mello. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
PloS one.
2019; 14(5):e0216327. doi:
10.1371/journal.pone.0216327. [PMID: 31063475] - Farina Muhammad Hanif, Rajesh Mandhwani, Ghullamullah Lail, Nasir Hassan Luck, Tahir Aziz. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.
2019 01; 17(Suppl 1):198-201. doi:
10.6002/ect.mesot2018.p64. [PMID: 30777554] - J Y Wei, D N Lin, Z B Wu, J Y Zhu, Z X Zhao, Y Y Mei, C S Lin, J Zhang, X H Zhang. [Safety and efficacy of DCV-based DAAs therapy for chronic HCV infection in China].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2018 Dec; 26(12):933-939. doi:
10.3760/cma.j.issn.1007-3418.2018.12.011. [PMID: 30669787] - Rasha Aboshabana, Shereen Shalan, Manal Eid, Nahed El-Enany. Two validated spectrofluorimeteric and high performance liquid chromatography (HPLC) methods with fluorescence detection for the analysis of a new anti-hepatitis C drug, daclatasvir hydrochloride, in raw material or tablet form and in biological fluids.
Luminescence : the journal of biological and chemical luminescence.
2018 Dec; 33(8):1333-1345. doi:
10.1002/bio.3551. [PMID: 30350338] - Kazuhiko Hayashi, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Yoshiki Hirooka, Hidenori Toyoda, Takashi Kumada, Masashi Hattori, Yoshiaki Katano, Hidemi Goto. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
Journal of viral hepatitis.
2018 12; 25(12):1446-1451. doi:
10.1111/jvh.12967. [PMID: 29993164] - Manoj Kumar, Suman L Nayak, Ekta Gupta, Ashish Kataria, Shiv K Sarin. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Liver international : official journal of the International Association for the Study of the Liver.
2018 12; 38(12):2137-2148. doi:
10.1111/liv.13863. [PMID: 29676846] - Hawwa Alao, Maggie Cam, Chithra Keembiyehetty, Fang Zhang, Elisavet Serti, Daniel Suarez, Heiyoung Park, Nicolaas H Fourie, Elizabeth C Wright, Wendy A Henderson, Qisheng Li, T Jake Liang, Barbara Rehermann, Marc G Ghany. Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Hepatology (Baltimore, Md.).
2018 12; 68(6):2078-2088. doi:
10.1002/hep.29921. [PMID: 29704252] - Pei-Bin Zhai, Jie Qing, Ben Li, Lin-Qi Zhang, Lan Ma, Li Chen. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
Acta pharmacologica Sinica.
2018 Nov; 39(11):1746-1752. doi:
10.1038/s41401-018-0046-2. [PMID: 29930277] - Takayo Ueno, Mayu Osawa, Yasuhiko Imai, Hiroki Ishikawa, Tushar Garimella. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
Journal of clinical pharmacology.
2018 11; 58(11):1479-1488. doi:
10.1002/jcph.1262. [PMID: 30063245] - Mayu Osawa, Takayo Ueno, Hiroki Ishikawa, Yasuhiko Imai, Tushar Garimella. Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Journal of clinical pharmacology.
2018 11; 58(11):1468-1478. doi:
10.1002/jcph.1274. [PMID: 30063254] - Ahmed Yahia Elmowafy, Hanzada Mohamed El Maghrabi, Mohamed Ahmed Zahab, Salwa Mahmoud Elwasif, Mohamed Adel Bakr. Sofosbuvir and Daclatsvir in Treatment of Hepatitis C Virus-related Membranoproliferative Glomerulonephritis With Cryoglobulinemia in a Patient With Hepatitis C Genotype 4.
Iranian journal of kidney diseases.
2018 Nov; 12(6):382-384. doi:
NULL. [PMID: 30595569] - Ashish Dogra, Shipra Bhatt, Asmita Magotra, Anjna Sharma, Pankul Kotwal, Abhishek Gour, Priya Wazir, Gurdarshan Singh, Utpal Nandi. Intervention of curcumin on oral pharmacokinetics of daclatasvir in rat: A possible risk for long-term use.
Phytotherapy research : PTR.
2018 Oct; 32(10):1967-1974. doi:
10.1002/ptr.6123. [PMID: 29806225] - Wafaa S Hassan, Manal S Elmasry, Heba M Elsayed, Dalia W Zidan. Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma, and dissolution test.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2018 Sep; 202(?):159-173. doi:
10.1016/j.saa.2018.05.041. [PMID: 29783148] - Noha N Atia, Salwa R El-Shaboury, Samia M El-Gizawy, Mohammad Nabil Abo-Zeid. Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Journal of pharmaceutical and biomedical analysis.
2018 Sep; 158(?):88-93. doi:
10.1016/j.jpba.2018.05.028. [PMID: 29864695] - Ola M Abdallah, Ahmed M Abdel-Megied, Amira S Gouda. Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method.
Luminescence : the journal of biological and chemical luminescence.
2018 Sep; 33(6):1094-1100. doi:
10.1002/bio.3514. [PMID: 30047624] - Noboru Harada, Tomoharu Yoshizumi, Toru Ikegami, Shinji Itoh, Norihiro Furusho, Masaki Kato, Shinji Shimoda, Takasuke Fukuhara, Yuji Soejima, Yoshihiko Maehara. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Anticancer research.
2018 Sep; 38(9):5513-5520. doi:
10.21873/anticanres.12885. [PMID: 30194210] - Victor Virlogeux, Pascale Berthillon, Isabelle Bordes, Sylvie Larrat, Stéphanie Crouy, Caroline Scholtès, Pierre Pradat, Marianne Maynard, Fabien Zoulim, Vincent Leroy, Isabelle Chemin, Christian Trépo, Marie-Anne Petit. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
Clinics and research in hepatology and gastroenterology.
2018 09; 42(4):313-318. doi:
10.1016/j.clinre.2018.02.002. [PMID: 29551607] - Manish Balwani, Charulata Bawankule, Vishal Ramteke, Amit Pasari. Hepatitis C virus, directly acting antivirals and Guillain-Barré syndrome.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.
2018 Sep; 29(5):1237-1239. doi:
10.4103/1319-2442.243969. [PMID: 30381528] - Sunil Taneja, Ajay Duseja, Arka De, Vivek Kumar, Raja Ramachandran, Ashish Sharma, Radha K Dhiman, Krishan L Gupta, Yogesh Chawla. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Nephrology (Carlton, Vic.).
2018 Sep; 23(9):876-882. doi:
10.1111/nep.13109. [PMID: 28703905] - NULL. 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Clinical and molecular hepatology.
2018 09; 24(3):169-229. doi:
10.3350/cmh.2018.1004. [PMID: 30092624] - Yash Gandhi, Timothy Eley, Aberra Fura, Wenying Li, Richard J Bertz, Tushar Garimella. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Clinical pharmacokinetics.
2018 08; 57(8):911-928. doi:
10.1007/s40262-017-0624-3. [PMID: 29353349] - Yuji Teraoka, Takuro Uchida, Michio Imamura, Nobuhiko Hiraga, Mitsutaka Osawa, Hiromi Kan, Yuhei Saito, Masataka Tsuge, Hiromi Abe-Chayama, C Nelson Hayes, Grace Naswa Makokha, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
The Journal of general virology.
2018 08; 99(8):1058-1065. doi:
10.1099/jgv.0.001091. [PMID: 29916799] - Satoshi Takakusagi, Ken Sato, Yuhei Suzuki, Yuichi Yamazaki, Takashi Kosone, Satoru Kakizaki, Motoyasu Kusano, Hitoshi Takagi. Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia.
Internal medicine (Tokyo, Japan).
2018 Aug; 57(15):2189-2195. doi:
10.2169/internalmedicine.9624-17. [PMID: 29526955] - Mohammad Nabil Abo-Zeid, Samia M El-Gizawy, Noha N Atia, Salwa R El-Shaboury. Efficient HPTLC-dual wavelength spectrodensitometric method for simultaneous determination of sofosbuvir and daclatasvir: Biological and pharmaceutical analysis.
Journal of pharmaceutical and biomedical analysis.
2018 Jul; 156(?):358-365. doi:
10.1016/j.jpba.2018.04.049. [PMID: 29753282] - Rebeca García-Agudo, Sami Aoufi-Rabih, Mercedes Salgueira-Lazo, Carmen González-Corvillo, Fabrizio Fabrizi. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
The International journal of artificial organs.
2018 Jul; 41(7):363-370. doi:
10.1177/0391398818763478. [PMID: 29582685] - Dalia W Zidan, Wafaa S Hassan, Manal S Elmasry, Abdalla A Shalaby. Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Jun; 1086(?):73-81. doi:
10.1016/j.jchromb.2018.04.011. [PMID: 29660665] - Jessica Cusato, Amedeo De Nicolò, Lucio Boglione, Fabio Favata, Alessandra Ariaudo, Simone Mornese Pinna, Chiara Carcieri, Federica Guido, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio. Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy.
Pharmacogenomics.
2018 06; 19(8):701-707. doi:
10.2217/pgs-2018-0009. [PMID: 29790402] - Ola M Abdallah, Ahmed M Abdel-Megied, Amira S Gouda. Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study.
Biomedical chromatography : BMC.
2018 Jun; 32(6):e4186. doi:
10.1002/bmc.4186. [PMID: 29314090] - Takeshi Hirayama, Tadashi Ikegami, Akira Honda, Teruo Miyazaki, Sho-Ichiro Yara, Motoyuki Kohjima, Makoto Nakamuta, Yasushi Matsuzaki. Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Internal medicine (Tokyo, Japan).
2018 May; 57(9):1219-1227. doi:
10.2169/internalmedicine.9479-17. [PMID: 29279486] - Mohammed Shujauddin Akhil, Balaji Kirushnan, Melvin Martin, Kanakaraj Arumugam, N K Ganesh Prasad, Rajan Ravichandran. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Nephrology (Carlton, Vic.).
2018 May; 23(5):446-452. doi:
10.1111/nep.13050. [PMID: 28339162]
